Astrazeneca’s Ceo as the Company Becomes the Third Pharmaceutical Company in Recent Weeks to Announce Promising Clinical Trial Results for a Covid-19 Vaccine.

November 23, 2020
Featured article image

Today marks an important milestone in our fight against the pandemic.

  • THE LATEST: AstraZeneca’s CEO says the “vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency. Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.”
    • Last week, Moderna announced the results of its Phase 3 COVID-19 vaccine trial show it’s nearly 95% effective.
      • Also last week, the U.S. gov’t granted emergency use authorization for a first of its kind at-home COVID-19 test that provides results in 30 min. or less. So far, it’s catching 94% of all positive cases, and 98% of all negative cases.
    • Two weeks ago, Pfizer announced the results of its Phase 3 COVID-19 vaccine trial show it’s over 90% effective. Pfizer became the first to apply for emergency use authorization from the FDA last week.
  • ABOUT THE ASTRAZENECA TRIALS: The trials involve over 23,000 participants in the UK and Brazil. The vaccine was developed by the University of Oxford and AstraZeneca using a weakened version of the common cold virus.
    • AstraZeneca says its vaccine is at least 62% effective (when given as a half dose followed by a full dose one month later) and up to 90% effective (when given as two full doses one month apart).
  • FYI: Unlike the other vaccines, the AstraZeneca vaccine does not need to be stored at ultra-cool temperatures, and it’s expected to be less expensive than those from Pfizer and Moderna.
  • BIG PICTURE: Health and Human Services Secretary Alex Azar said last week that he expects the U.S. will have 40 million doses of vaccines available for high-risk and vulnerable populations, such as frontline workers, by the end of the year.

by Jenna Lee,

ImageImageImageImage